Industry in brief | Karo, Probi, Enzymatica
23 July 2021
Karo Pharma, Probi and Enzymatica have released financial results.
Industry News
You can read our Premium News Service in full if you have an Annual Subscription to the OTCToolbox website. You can read Basic News stories free of charge.
Retail in brief | API, GNC, Shop Apotheke Europe
22 July 2021
Wesfarmers has made a takeover offer for Australian Pharmaceutical Industries (API), GNC has announced two changes to its leadership team, and Shop Apotheke Europe has released financial results.
Recordati recruits Koremans as chief executive
Premium
21 July 2021
Recordati has appointed former Teva executive Rob Koremans as its new chief executive officer with effect from 1 December 2021.
German committee backs three OTC switches
Premium
15 July 2021
Germany’s Expert Committee for Prescription has recommended switches from prescription to non-prescription status for two pain relievers and a cough suppressant.
Stada launches Austria’s first OTC triptan
15 July 2021
Stada has launched Austria’s first non-prescription migraine treatment containing a triptan. The Austrian initiative was “tailored to the local market conditions and opportunities”, Stada told OTCToolbox, adding that the company “continues to explore opportunities for prescription-to-OTC switches wh...
Products in brief | Biotrue, AleveX, Maxigesic
15 July 2021
Bausch Health Companies has extended its Biotrue eyecare brand in the US, Bayer Consumer Health is backing the launch of AleveX with a golf-themed campaign, and AFT Pharmaceuticals has received regulatory approval for Maxigesic Oral Liquid in two countries.
Marc Coucke to sell Ceres Pharma to Naxicap
Premium
15 July 2021
Consumer healthcare entrepreneur Marc Coucke is selling his interests in Ceres Pharma to French private-equity firm Naxicap Partners for an undisclosed sum.
Hypera to acquire portfolio of brands from Sanofi
Premium
14 July 2021
Brazil’s Hypera Pharma is acquiring a portfolio of OTC and prescription brands – including the analgesic AAS and the herbal medicine Naturetti – from Sanofi for USD190 million.
Stada and Enzymatica add Vietnam to partnership
Premium
13 July 2021
Stada has inlicensed exclusive rights to Enzymatica’s ViruProtect in Vietnam and plans to launch the common cold spray in the country in 2022.
Enzymatica promotes Egstrand to chief executive
Premium
13 July 2021
Enzymatica – the Swedish company behind the ColdZyme common cold spray – has promoted Claus Egstrand to chief executive officer.